<DOC>
	<DOCNO>NCT02925975</DOCNO>
	<brief_summary>The aim study investigate possibility early precise management decrease portal vein pressure cirrhotic patient , guide non-invasive 3D-virtual-model hepatic portal system ( 3D-vHPS ) . Healthy volunteer enrol determine normal range pressure density different site HPS . Cirrhotic patient without visible gastro-esophageal varies endoscopy randomly enrol virtual portal vein pressure gradient ( vPVPG ) monitor non-vPVPG monitored group . Non-vPVPG group followed-up treat accord Baveno V consensus portal hypertension . Patients vPVPG-monitored group followed-up anatomic compute tomographic angiography ( CTA ) Doppler ultrasound every six month . Once vPVPG 12mmHg , participant receive carvedilol treatment . All cirrhotic patient followed-up incidence portal hypertension-related complication , mortality rate life quality assessment .</brief_summary>
	<brief_title>Early Precise Diagnosis Intervention CPT Based Noninvasive 3D-vHPS</brief_title>
	<detailed_description>The non-invasive 3D-HPS newly-developed test determine vPVPG base anatomic computed tomographic angiography ( CTA ) Doppler ultrasound . In study , vPVPG determine 3D-HPS .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Proven cirrhosis base histology unequivocal clinical , sonographic laboratory finding ChildPugh score &lt; 9 No visible gastroesophageal varies endoscopy Patients malignant disease Treatment vasoactive drug Prior transjugular intrahepatic portosystemic stentshunt surgery Patients know allergy iodinated contrast Treatment immunosuppressants Renal sufficiency Patients coronary artery disease , treat anticoagulant Pregnancy Inability adhere followup Any lifethreatening disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>